Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

The study assessed the safety of lenvatinib and sorafenib in 71 patients with advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer in Korea. Lenvatinib was associated with higher incidences of hypertension, QT prolongation, and proteinuria, while sorafenib had higher incidences of hand-foot skin reactions, alopecia, and rash. Both drugs required dose modifications due to adverse events, with 17.4% of lenvatinib and 54.2% of sorafenib patients discontinuing treatment. No new safety concerns were identified, but adverse events like hypertension and proteinuria required close monitoring. Most adverse events were managed with dose adjustments and medical therapy.